The Evolving Science of Dilated Cardiomyopathy.
The Evolving Science of Dilated Cardiomyopathy.
复制标题
扩张型心肌病的不断发展的科学。
DOI：
10.1016/j.jacc.2021.08.038
复制
发表时间：
2021
影响因子：
24
通讯作者：
Hershberger,RayE
中科院分区：
文献类型：
--
作者：
Hershberger,RayE
在本期杂志中，由马德里Garcia-Pavia小组领导的Escobar-Lopez等人（1）解决了扩张型心肌病（DCM）遗传学问题：DCM患者是否会根据其疾病基因产生不同的结果？这是一个重要而尚未解决的临床问题。从20家西班牙医院回顾性收集了1,005名年龄> 15岁的DCM患者（先证者）的临床数据，这些患者在2015年至2020年期间接受了DCM基因测序。该研究的主要终点是主要不良心血管事件（MACE），其定义为终末期心力衰竭，严重室性心律失常或中风。次要结局包括这些的特定方面加上左心室逆向重构，其定义为左心室射血分数（LVEF）改善> 50%或LVEF增加10美元。中位随访时间为4年。遗传分析基于美国医学遗传学和基因组学学院2015标准。
In this issue of the Journal, Escobar-Lopez et al (1), led by the Garcia-Pavia group in Madrid, address a question of dilated cardiomyopathy (DCM) genetics: Do DCM patients have different outcomes based on their disease genes? This is an important and unresolved clinical question. From 20 Spanish hospitals, clinical data were retrospectively collected from 1,005 DCM patients (probands) aged> 15 years who had undergone DCM gene sequencing between 2015 and 2020. The study’s primary endpoint was major adverse cardiovascular events (MACEs), which were defined as end-stage heart failure, major ventricular arrhythmias, or stroke. Secondary outcomes included specific aspects of these plus left ventricular reverse remodeling, which was defined as left ventricular ejection fraction (LVEF) improvement> 50% or an increase of $10 LVEF points. The median follow-up was 4 years. Genetic analysis was based on the American College of Medical Genetics and Genomics 2015 criteria.